Advocacy is the act of supporting a cause or idea. It involves speaking out on issues that you care about and offering ways to improve upon them.
Anyone can become an advocate! The IMF's multiple myeloma cancer advocacy group helps guide individuals to advocate for critical health issues that affect the multiple myeloma community. Whether you are a patient, caregiver, doctor, nurse, or friend, your opinion does matter. The only way we can make a difference is to TAKE ACTION!
The Cancer Drug Parity Act (H.R. 1730 in the House and S. 741 in the Senate) ensures fairness in cost-sharing for all anticancer regimens. Health insurance cost-sharing schemes should not create barriers to cancer patients' ability to access potentially life-saving medicines.
On January 17, 2019, The IMF joined with over 50 patient advocacy groups in an ad campaign to ensure Medicare Part D patients continue to have access to drugs in the Six Protected Classes, which include many drugs used to treat cancer.
H.R. 913 aims to improve access to clinical trials for Medicaid enrollees by requiring states to provide coverage of routine patient costs in connection with participation in qualifying clinical trials.
Our Advocacy Team conveys to the Administration the perspectives and experiences of myeloma patients affected by high out-of-pocket drug costs.
Subscribe to receive advocacy alerts and campaign notices.